What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for RHHBY (
Roche Holding AG
) from 2002 to Apr 27 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Roche Holding AG stock (RHHBY) PE ratio as of Apr 27 2025 is 25.4.
More Details
Roche Holding AG (RHHBY) PE Ratio (TTM) Chart
Roche Holding AG (RHHBY) PE Ratio (TTM) Historical Data
View and export this data going back to 2002. Start your Free Trial
Total 1214
- 1
- 2
- 3
- 4
- 5
- 6
- 14
Roche Holding AG PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2025-04-27 | 27.4 | 2025-02-21 | 28.7 |
2025-04-25 | 27.4 | 2025-02-20 | 28.5 |
2025-04-24 | 27.6 | 2025-02-19 | 28.2 |
2025-04-23 | 27.1 | 2025-02-18 | 28.3 |
2025-04-22 | 27.0 | 2025-02-14 | 28.4 |
2025-04-21 | 26.9 | 2025-02-13 | 28.6 |
2025-04-17 | 27.0 | 2025-02-12 | 27.9 |
2025-04-16 | 26.7 | 2025-02-11 | 27.3 |
2025-04-15 | 26.7 | 2025-02-10 | 27.6 |
2025-04-14 | 26.5 | 2025-02-07 | 27.6 |
2025-04-11 | 26.4 | 2025-02-06 | 27.4 |
2025-04-10 | 25.5 | 2025-02-05 | 28.1 |
2025-04-09 | 25.7 | 2025-02-04 | 27.5 |
2025-04-08 | 24.9 | 2025-02-03 | 27.3 |
2025-04-07 | 24.9 | 2025-01-31 | 27.2 |
2025-04-04 | 26.1 | 2025-01-30 | 27.6 |
2025-04-03 | 27.7 | 2025-01-29 | 26.9 |
2025-04-02 | 27.3 | 2025-01-28 | 27.0 |
2025-04-01 | 28.5 | 2025-01-27 | 27.1 |
2025-03-31 | 28.5 | 2025-01-24 | 26.4 |
2025-03-28 | 29.1 | 2025-01-23 | 26.4 |
2025-03-27 | 29.4 | 2025-01-22 | 26.2 |
2025-03-26 | 29.5 | 2025-01-21 | 26.0 |
2025-03-25 | 30.1 | 2025-01-17 | 25.2 |
2025-03-24 | 29.7 | 2025-01-16 | 25.4 |
2025-03-21 | 30.3 | 2025-01-15 | 25.3 |
2025-03-20 | 30.1 | 2025-01-14 | 25.1 |
2025-03-19 | 30.1 | 2025-01-13 | 25.1 |
2025-03-18 | 30.5 | 2025-01-10 | 25.3 |
2025-03-17 | 30.7 | 2025-01-08 | 25.4 |
2025-03-14 | 30.0 | 2025-01-07 | 25.3 |
2025-03-13 | 29.7 | 2025-01-06 | 24.6 |
2025-03-12 | 30.2 | 2025-01-03 | 24.4 |
2025-03-11 | 29.1 | 2025-01-02 | 24.2 |
2025-03-10 | 29.8 | 2024-12-31 | 24.2 |
2025-03-07 | 30.4 | 2024-12-30 | 24.4 |
2025-03-06 | 29.8 | 2024-12-27 | 18.7 |
2025-03-05 | 29.4 | 2024-12-26 | 18.6 |
2025-03-04 | 29.5 | 2024-12-24 | 18.6 |
2025-03-03 | 29.0 | 2024-12-23 | 18.6 |
2025-02-28 | 28.9 | 2024-12-20 | 18.4 |
2025-02-27 | 28.7 | 2024-12-19 | 18.2 |
2025-02-26 | 29.1 | 2024-12-18 | 18.6 |
2025-02-25 | 29.0 | 2024-12-17 | 19.1 |
2025-02-24 | 28.8 | 2024-12-16 | 18.9 |
Roche Holding AG (RHHBY) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description

Roche Holding AG
NAICS : 325412
SIC : 2834
ISIN : US7711951043
Share Class Description:
RHHBY: ADRCompare
Compare
Traded in other countries / regions
ROG.SwitzerlandRHHBY.USA0QOK.UKROG.CanadaROG N.MexicoRHO6.Germany IPO Date
2002-12-05Description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.